The Vanguard Group 13D and 13G filings for Iovance Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:07 pm Purchase |
2023-12-29 | 13G | Iovance Biotherapeutics, Inc. IOVA |
The Vanguard Group | 22,812,820 8.910% |
8,349,738 (+57.73%) |
Filing |
| 2023-02-09 11:22 am Purchase |
2022-12-30 | 13G | Iovance Biotherapeutics, Inc. IOVA |
The Vanguard Group | 14,463,082 9.160% |
2,265,295 (+18.57%) |
Filing |
| 2022-02-10 08:17 am Purchase |
2021-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
The Vanguard Group | 12,197,787 7.770% |
332,405 (+2.80%) |
Filing |
| 2021-02-10 11:10 am Purchase |
2020-12-31 | 13G | Iovance Biotherapeutics, Inc. IOVA |
The Vanguard Group | 11,865,382 8.090% |
1,012,253 (+9.33%) |
Filing |